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Abstract
We report here a 44-year-old Moroccan man with resectable gastric adenocarcinoma with overexpression of
human epidermal growth factor receptor 2 (HER2) by immunohistochemistry who was treated with trastuzumab in
combination with chemotherapy in perioperative setting. He received 3 cycles of neoadjuvant chemotherapy
consisting of trastuzumab, oxaliplatin, and capecitabine. Afterwards, he received total gastrectomy with extended
D2 lymphadenectomy without spleno-pancreatectomy. A pathologic complete response was obtained with a
combination of trastuzumab and oxaliplatin and capecitabine. He received 3 more cycles of trastuzumab
containing regimen postoperatively.
We conclude that resectable gastric carcinoma with overexpression of the c-erbB-2 protein should ideally be
managed with perioperative combination of trastuzumab with chemotherapy. Further research to evaluate
trastuzumab in combination with chemotherapy regimens in the perioperative and adjuvant setting is urgently
needed.
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Background
Gastric cancer is the second largest cause of cancer
associated death world-wide. Surgery remains the main-
stay of treatment for the resectable cancer. However
with the noted high frequency of loco regional and dis-
tant recurrences and relatively low 5-year survival for
symptomatic Stage II-III and Stage IV cancer (20-50%
and 5-10%, respectively), there has been a need to
develop more effective peri-operative and adjuvant
therapies for Stage II-IV disease [1] and in some coun-
tries with a high incidence of gastric cancer (such as
Japan) screening programs have been established for the
detection of Stage I resectable disease which has a 90%
chance of 5-year survival [1]. Perioperative chemother-
apy has been shown to cause tumor down staging and
improve survival in patients with resectable gastric
cancer [2]. Response to neoadjuvant treatment is the
most important predictor of survival after curative
resection of gastric cancer [3,4]. More recently several
novel approaches based on molecular targeting have
also been attempted including the use of anti-VEGF [5],
EGFR [6] or HER2 [7] monoclonal antibodies combined
with chemotherapy. In this case report, we describe a
case of neoadjuvant chemotherapy with trastuzumab-
containing regimen in gastric cancer. We discuss histo-
pathological effect and review the literatures.
Case presentation
At the end of April 2010 a healthy 44 years Old Moroc-
can male without medical history was admitted at our
institution for incoercible vomiting with moelena. He
underwent oesophageogastroduodenoscopy witch
showed a 3-cm gastric polypoides lesions on the lesser
curvature proximal to angularis. Specimen Gastric
biopsy revealed an infiltrating well differentiated adeno-
carcinoma. Tumor analysis for human epidermal growth
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ventana indicating a Strong complete, basolateral mem-
branous reactivity in > 80% of the tumor cells in favor
of 3+ immunohistochemistry (IHC) staining (Figure 1).
Staging workups, including computed tomography (CT)
scan of chest, abdomen and pelvis showed a circumfer-
ential and irregular thickening fundic area arriving in
contact with body pancreas without infiltration sign
without loco regional lymph node. Triphasic (CT)
revealed a lesion involving segments 4, 5 and 7 of the
liver. It was centrally hypodense with peripheral
enhancement in the arterial phase suggesting an angio-
matose lesions or secondary localizations. Positron
Emission Tomography-CT scan was not available. In
front of this doubt about hepatic lesions, endoscopic
ultrasound was not retained and platinum based che-
motherapy regimen including Capecitabine (2000 mg/
m
2/j) po bid on day 1 to day 14 plus oxaliplatin (130
mg/m
2/j) on day 1 were given every 3 weeks. Trastuzu-
mab (intravenously, 8 mg/kg loading dose, then 6 mg/kg
on days 1-21 of every cycle) was started at the end of
MAY 2010 and administered concommittally with che-
motherapy for three cycles. Post CT scan evaluation
showed a gastric partial response with stability of hepa-
tic lesions. Hepatic Magnetic Resonance Imagery with
diffusion technique objective of atypical hemangioma
lesion. Therapeutic strategy was reconsidered and total
gastrectomy with extended D1.5 lymph node dissections,
Roux-en-Y esophagojejunostomygastric surgery was
practiced in August 2010. Prior to surgical resection,
laparoscopy revealed no evidence of peritoneal carcino-
matosis or metastatic implants. Pathological examination
of the surgical specimen indicated no residual adenocar-
c i n o m ab u ts c a ro nl e s s e rc u r v a t u r ew i t hf i b r o s i s
extending into muscularis propria (Figure 2). There
were no tumor identified in 24 perigastric lymph nodes
and 2 lymph nodes from porta hepatis. He recovered
uneventfully after surgery, and received 3 more cycles of
chemotherapy consisting of trastuzumab, oxaliplatine.
After gastrectomy, our patient presented loss of appetite,
and dietary problems. Most important advice (to eat
small, frequent meals) following a gastrectomy was pro-
posed. Oral Capecitabine was substituted by intravenous
perfusion of 5FU for 96 hours. Last cycle of treatment
was given in November 2010. He has remained free of
disease after completion of chemotherapy. We have
monitored our patient’s cardiac function with periodic
echocardiogram evaluation, and find no evidence of car-
diac failure. Most common toxicities were (grade 1)
neuropathy and hand-foot syndrome. Currently, the
patient is under monitoring. He underwent periodic fol-
low-up with CT scan. He received intramuscular supple-
mentation of vitamin B12. He is in good health without
recurrence for 15 months.
Conclusion
HER2 protein over expression by immunohistochemistry
(IHC) and/or erB2 gene amplification by in situ hybridi-
zation was detected in 4-28% of gastric or gastro-oeso-
phageal junction cancers (GOJ) [8]. HER2/neu positivity
rates have been reported to be more frequent in intest-
inal type gastric cancer (21.5%) than in diffuse gastric
cancer (2%) or mixed types (5%) [9]. Most studies have
shown that HER2-overexpressing gastric cancers were
worse prognosis and have been shown to be an
Figure 1 Immunohistochemical study of HER2 protein in
biopsied specimen before chemotherapy. The well differentiated
adenocarcinoma cells infiltrated the gastric sub mucosa and Strong
complete, basolateral membranous reactivity in > 80% of the tumor
cells in favor of over expressed HER2 (3+ by HercepTest) on the cell
membrane (immunoperoxidase stain, 100×).
Figure 2 Microscopic finding of the resected specimen after
chemotherapy. No residual adenocarcinoma was found in the
original ulcerated adenocarcinoma site on lesser curvature. Instead,
it was completely replaced by dense fibrous tissue (hematoxylin
eosin stain, 100×).
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humanized monoclonal antibody directed against HER2
with known efficacy in patients with HER2+ early or
metastatic breast cancer. Results from the largest study
to date (ToGA trial) evaluating the addition of trastuzu-
mab to chemotherapy in HER2-positive advanced gastric
cancer (AGC) were reported at the 2009 American
Society Clinical Oncology (ASCO) meeting [11]. The
Trastuzumab for Gastric Cancer (ToGA) trial is the first
randomized Phase III trial providing prospective infor-
mation on HER2-positivity rates in AGC. The trial
enrolled 3,883 patients from 24 countries. A HER2-scor-
ing system modified from the protocol in breast cancer
was used: a score of IHC 3+ and/or FISH positive was
defined as HER2 positive. The modified HER2-scoring
system showed concordance between IHC and FISH
results of 87.5%. In breast cancer most IHC 0/1 samples
are FISH negative but, in the ToGA cohort, the fre-
quency of IHC 0/1 samples testing FISH positive was
almost as high as IHC 2/FISH-positive samples (23% vs.
26%). The study reported an overall HER2-positivity
rate of 22.1% evaluated from 3807 patients. In the
ToGA trial, patients with HER2-positive gastroesopha-
geal and gastric adenocarcinoma (locally advanced,
recurrent, or metastatic) were randomized to receive
Trastuzumab plus chemotherapy (5-fluorouracil or cape-
citabine and cisplatin) q3w for 6 cycles or chemotherapy
alone. The primary end point was overall survival (OS);
secondary end points included overall response rate
(ORR), progression-free survival, time to progression,
duration of response, and safety. Median OS was signifi-
cantly improved with Trastuzumab plus chemotherapy
compared to chemotherapy alone: 13.5 vs. 11.1 months,
respectively (p = 0.0048; HR 0.74; 95% CI 0.60, 0.91).
(ORR) was 47.3% in the Trastuzumab plus chemother-
apy arm and 34.5% in the chemotherapy arm (p =
0.0017). This first randomized trial investigating anti-
HER2 therapy in AGC showed that Trastuzumab plus
chemotherapy is superior to chemotherapy alone. The
OS benefit indicates that trastuzumab is a new, effective,
and well-tolerated treatment for HER2-positive AGC.
The benefit was even greater in the subgroup with
HER2 overexpression (16% of the screened population)
as defined by IHC3+ or IHC2+ confirmed by positive
ISH test [12]. Trastuzumab plus FP chemotherapy has
become the standard treatment for patients with HER2+
non-pretreated metastatic adenocarcinoma of the sto-
mach or GOJ cancer. The MAGIC trial showed that
patients treated with Perioperative epirubicin, cisplatin,
and 5-fluorouracil had significantly higher overall survi-
val compared to patients treated with surgery alone (5-
year survival: 36% for chemotherapy plus surgery vs.
23% for surgery). At the time of surgery, the patients
receiving preoperative chemotherapy had significantly
smaller tumor size and lower stage. However, there was
no pathological complete response in patients receiving
preoperative ECF in this study [2]. The infusional 5-FU
in the ECF regimen is given continuously through a
venous access device, and is associated with inconveni-
ence and higher incidence of thrombosis and infection.
Furthermore, cisplatin can cause nephrotoxicity, ototoxi-
city, and severe emesis. The benefit for preoperative
chemotherapy was also noted in a French multicenter
trial in which 224 patients with potentially resectable
stage II or greater adenocarcinoma of the stomach (n =
55), GE junction (n = 144) or distal esophagus (n = 25)
were randomly assigned to two to three cycles of preo-
perative chemotherapy (infusional 5-FU 800 mg/m2
daily for five days plus cisplatin 100 mg/m2 on day 1 or
2, every four weeks) or surgery alone. In a Final report,
patients undergoing neoadjuvant chemotherapy were
significantly more likely to undergo R0 (microscopically
complete) resection (87 versus 74 percent), and there
was a statistically insignificant trend toward fewer pT3/4
(58 versus 68 percent) and fewer node-positive tumors
(67 versus 80 percent) that favored this group as well.
With a median 5.7-year follow-up, neoadjuvant che-
motherapy was associated with a significant 35 percent
reduction in the risk of disease recurrence (five-year dis-
ease-free survival 34 versus 21 percent) and a significant,
31 percent lower risk of death (five-year survival 38 ver-
sus 24 percent) [13]. REAL-2, a randomized study in
patients with advanced gastroesophageal cancer using
two-by-two design, has shown 5-FU can be replaced by
capecitabine and cisplatin by oxaliplatin in the regimen
of ECF without affecting the efficacy [14]. Other studies
also show that oxaliplatin can be substituted for cispla-
tin [15] and Capecitabine for 5-FU in chemotherapy
doublets [16], preserving efficacy and offering some toxi-
city benefits. A recent meta-analysis has shown that
Capecitabine is superior to infused 5-FU for OS within
doublet and triplet regimes for advanced gastric cancer
[17]. Initially our patient was considered metastatic at
baseline and Trastuzumab based regimen was received
as standard treatment. Substitution of oxaliplatin and
Capecitabine was based on increased tolerance of with-
out efficacy loss in advanced setting. Hepatic heman-
gioma lesion showed in magnetic resonance imagery led
us to reconsider disease stage and propose curative ther-
apeutic strategy. He received total gastrectomy with
extended D1.5 lymph node dissections showing patholo-
gical complete response significantly influencing relapse-
free survival, overall survival. This information was
observed in locally invasive breast cancer. The results of
3 large phase III trials (the M. D. Anderson Cancer Cen-
ter neoadjuvant trastuzumab trial, the Neoadjuvant Her-
ceptin [NOAH] trial, and the German Breast Group/
G y n e c o l o g i cO n c o l o g yS t u d yG r o u p“GeparQuattro”
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alone, neoadjuvant trastuzumab plus chemotherapy sig-
nificantly increased pathologic complete response rates
to as high as 65%, improvements in disease-free, event-
free, and overall survival [17-19]. However, the question
which arose was the duration of trastuzumab. it’s neces-
sary to manage for 12 months by extrapolation from
adjuvant breast cancer or to be satisfied with 6 cycles in
totality?. The answer to this question requires a large
randomized phase III or II study. Our case illustrates
the case of pathological complete response after neoad-
juvant chemotherapy with trastuzumab-containing regi-
men in a patient with locally gastric cancer over
expressing HER2. The use of oxaliplatin and capecita-
bine in combination with trastuzumab in this setting
remains experimental, and ideally should be considered
only in the context of a clinical trial. Therefore, the role
of trastuzumab as a part of perioperative therapy is
worth further investigation. Multidisciplinary evaluation
plays a crucial role in the management of these patients.
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